The Patent Finder

Obi Pharma, Inc.

23 patents currently held · Updated Nov 22, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2034
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 30, 2027
    The maintenance fee for DNA alkylating agents (US 10,364,261) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
  • 2 fees due Mar 10 to 12, 2027 · next Mar 10
  • 1 fee due Apr 3, 2027
    The maintenance fee for Methods of Making High Enantioselective Secondary Alcohols (US 11,773,118) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
  • 3 fees due Jun 5 to 30, 2027 · next Jun 5

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,517,936Vaccines with Higher Carbohydrate Antigen Density and Novel Saponin Adjuvant
In force
 · High confidence
In forceHigh confidence
US 11,752,204Vaccines with Higher Carbohydrate Antigen Density and Novel Saponin Adjuvant
In force
 · High confidence
In forceHigh confidence
US 12,053,514Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
In force
 · USPTO record
In forceUSPTO record
US 10,815,307Antibodies, Pharmaceutical Compositions and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,364,261DNA alkylating agents
In force
 · USPTO record
In forceUSPTO record
US 10,766,914DNA alkylating agents
In force
 · USPTO record
In forceUSPTO record
US 10,829,437Nitrobenzyl derivatives of anti-cancer agents
In force
 · USPTO record
In forceUSPTO record
US 11,535,585Nitrobenzyl derivatives of anti-cancer agents
In force
 · USPTO record
In forceUSPTO record
US 10,409,869(R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation
In force
 · USPTO record
In forceUSPTO record
US 10,501,532Novel Carbohydrate Antibodies, Pharmaceutical Compositions and Uses Thereof
In force
 · High confidence
In forceHigh confidence
10 of 23 patents shown.
Pro members see all 23.
Pro members: see all 23 patents
Also on record, not counted in the 23: 3 patents in force now held by others · 2 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 2 abandoned · 8 no status recorded

Showing 1 to 10 of 15, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/253,986Bispecific Dendritic Cell Engager and Uses ThereofJun 30, 2025Pending
18/862,675Synthesis Methods of Acyl Chain of QS-21 and Derivative ThereofMay 5, 2023Pending
18/685,917Bispecific Dendritic Cell Engager and Uses ThereofAug 30, 2022Pending
18/264,563Novel Carbohydrate Antibodies, Pharmaceutical Compositions and Uses ThereofFeb 9, 2022Abandoned
18/259,277Feb 9, 2022No status recorded
18/253,576Active Cancer Immunotherapy by Immune Modulation via Globo Series AntigensNov 19, 2021Abandoned
18/288,215Combination Therapy by Using AKR1C3-ACTIVATED Compound with Immune Checkpoint InhibitorApr 28, 2021Pending
18/261,137Use of AKR1C3-ACTIVATED CompoundFeb 26, 2021Pending
17/789,796Dec 30, 2020No status recorded
17/006,881Aug 30, 2020No status recorded
10 of 15 applications shown.
Pro members see all 15 published applications.
Pro members: see all 15 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited